Skip to main content
SpringerLink
Log in

Estrogens in Prostate Cancer

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2941 Accesses

Abstract

Although prostate cancer represents a major health issue in men in Western countries, being a common cause of morbidity and mortality after the age of 50, it ought to be preventable and curable. Notwithstanding, despite the most recent advances in both basic and translational research, the molecular basis of prostate cancer remains poorly understood. In particular, the mechanisms underlying development and progression of this neoplasm appear to be complex: genetic and environmental factors (notably lifestyle and diet), along with endogenous sex hormones and host immune and inflammatory response, are likely to be interconnected in the pathogenesis of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 2004;4:519–27.

    Article  PubMed  CAS  Google Scholar 

  2. Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology. 2001;57(Suppl 4A):31–8.

    Article  PubMed  CAS  Google Scholar 

  3. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102:899–911.

    Article  PubMed  CAS  Google Scholar 

  4. Kuiper GGJM, Carlquist M, Gustafsson JA. Estrogen is a male and female hormone. Sci Med. 1998;5:36–45.

    CAS  Google Scholar 

  5. American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society; 2012.

    Google Scholar 

  6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  7. Cancel-Tassin G, Cussenot O. Genetic susceptibility to prostate cancer. Br J Urol Int. 2005;96:1380–5.

    Article  CAS  Google Scholar 

  8. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control. 1996;7:83–94.

    Article  PubMed  CAS  Google Scholar 

  9. Giovannucci E, Leitzman M, Speigelman D, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. A prospective study of physical activity and prostate cancer in male health professionals. Cancer Res. 1998;58:5117–22.

    PubMed  CAS  Google Scholar 

  10. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. 1999;91:414–28.

    Article  PubMed  CAS  Google Scholar 

  11. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–413.

    Article  PubMed  CAS  Google Scholar 

  12. Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer. 1991;67:746–63.

    Article  PubMed  CAS  Google Scholar 

  13. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152–5.

    Article  PubMed  CAS  Google Scholar 

  14. Ganry O. Phytoestrogens and prostate cancer risk. Prev Med. 2005;41:1–6.

    Article  PubMed  CAS  Google Scholar 

  15. Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer. 2005;117:667–9.

    Article  PubMed  CAS  Google Scholar 

  16. Lampe JW. Emerging research on equol and cancer. J Nutr. 2010;140:1369S–72.

    Article  PubMed  CAS  Google Scholar 

  17. Ganmaa D, Li XM, Qin LQ, et al. The experience of Japan as a clue to the etiology of testicular and prostate cancer. Med Hypotheses. 2003;60:724–30.

    Article  PubMed  CAS  Google Scholar 

  18. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–75.

    Article  PubMed  CAS  Google Scholar 

  19. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002;5:98–102.

    PubMed  CAS  Google Scholar 

  20. King KJ, Nicholson HD, Assinder SJ. Effect of increasing ratio of estrogen:androgen on proliferation of normal and human prostate stromal and epithelial cells and the malignant cell line LNCaP. Prostate. 2006;66:105–14.

    Article  PubMed  CAS  Google Scholar 

  21. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001;22:319–41.

    Article  PubMed  CAS  Google Scholar 

  22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1–13.

    Article  PubMed  CAS  Google Scholar 

  23. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol. 2007;23:374–82.

    Article  PubMed  CAS  Google Scholar 

  24. Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP. Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology. 2000;141:3471–7.

    Article  PubMed  CAS  Google Scholar 

  25. Maffini MV, Rubin BS, Sonnenschein C, Soto AM. Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol Cell Endocrinol. 2006;254–255:179–86.

    Article  PubMed  CAS  Google Scholar 

  26. Trosko JE. Stem cells and cell-cell communication in the ­understanding of the role of diet and nutrients in human diseases. J Fd Hyg Safety. 2007;22:1–14.

    Google Scholar 

  27. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999;80:930–4.

    Article  PubMed  CAS  Google Scholar 

  28. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002;52:213–35.

    Article  PubMed  CAS  Google Scholar 

  29. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–26.

    Article  PubMed  CAS  Google Scholar 

  30. Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:621–5.

    PubMed  CAS  Google Scholar 

  31. Dorgan JF, Albanes D, Viriamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J, Taylor PR. Relationships of serum androgens and estrogens to prostate cancer risk: Results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7:1069–74.

    PubMed  CAS  Google Scholar 

  32. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50:169–73.

    PubMed  CAS  Google Scholar 

  33. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262–9.

    Article  PubMed  CAS  Google Scholar 

  34. Wiren S, Stocks T, Rinaldi S, et al. Androgens and prostate cancer risk: a prospective study. Prostate. 2007;67:1230–7.

    Article  PubMed  CAS  Google Scholar 

  35. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. Int J Cancer. 2004;108:418–24.

    Article  PubMed  CAS  Google Scholar 

  36. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology. 2006;68:1263–7.

    Article  PubMed  Google Scholar 

  37. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163:824–7.

    Article  PubMed  CAS  Google Scholar 

  38. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–8.

    Article  PubMed  CAS  Google Scholar 

  39. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate ­cancer. Am J Clin Oncol. 1997;20:605–8.

    Article  PubMed  CAS  Google Scholar 

  40. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–5.

    Article  PubMed  Google Scholar 

  41. Isom-Batz G, Bianco Jr FJ, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935–7.

    Article  PubMed  CAS  Google Scholar 

  42. Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J. 2001;48:573–8.

    Article  PubMed  CAS  Google Scholar 

  43. Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev. 2000;9:403–12.

    PubMed  CAS  Google Scholar 

  44. Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, Komiya A, Nihei N, Naya Y, Ichikawa T. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol. 2008;15:472–80.

    Article  PubMed  CAS  Google Scholar 

  45. van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985;45:2900–6.

    PubMed  Google Scholar 

  46. Castagnetta L, Granata OM, Traina A, Ravazzolo B, Amoroso M, Miele M, Bellavia V, Agostara B, Carruba G. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res. 2002;8:3146–55.

    PubMed  CAS  Google Scholar 

  47. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD. Estrogen – the good, the bad, and the unexpected. Endocr Rev. 2005;26:322–30.

    Article  PubMed  CAS  Google Scholar 

  48. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pellitier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24:152–82.

    Article  PubMed  CAS  Google Scholar 

  49. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270–82.

    Article  PubMed  CAS  Google Scholar 

  50. Farnsworth WE, Brown JR. Androgen of the human prostate. Endocr Res Commun. 1976;3:105–17.

    Article  PubMed  CAS  Google Scholar 

  51. Geller J, Albert J, de la Vega D, Loza D, Stoeltzing W. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency. Cancer Res. 1978;38:4349–52.

    PubMed  CAS  Google Scholar 

  52. Wilson JD. Role of dihydrotestosterone in androgen action. Prostate Suppl. 1996;6:88–92.

    Article  PubMed  CAS  Google Scholar 

  53. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008;72:247–54.

    Article  PubMed  Google Scholar 

  54. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009;1155:43–56.

    Article  PubMed  CAS  Google Scholar 

  55. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.

    Article  PubMed  CAS  Google Scholar 

  56. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol. 2006;176:1387–91.

    Article  PubMed  CAS  Google Scholar 

  57. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546–54.

    PubMed  Google Scholar 

  58. Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J Steroid Biochem Mol Biol. 2010;118:246–51.

    Article  PubMed  CAS  Google Scholar 

  59. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology. 2001;142:2458–67.

    Article  PubMed  CAS  Google Scholar 

  60. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in ­malignancy. J Clin Endocrinol Metab. 2004;89:2434–41.

    Article  PubMed  CAS  Google Scholar 

  61. Moeller G, Adamski J. Integrated view on 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 2009;301:7–19.

    Article  PubMed  CAS  Google Scholar 

  62. Takahashi M, Shimomoto T, Miyajima KM, et al. Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-methyl-N′-nitro-N-nitrosourea. Cancer Lett. 2004;211:1–9.

    Article  PubMed  CAS  Google Scholar 

  63. Carruba G, Granata OM, Pala V, Campisi I, Agostara B, Cusimano R, Ravazzolo B, Traina A. A traditional mediterranean diet decreases endogenous estrogens in healthy postmenopausal women. Nutr Cancer. 2006;56:253–9.

    Article  PubMed  CAS  Google Scholar 

  64. Bradlow H, Telang N, Sepkovic D, Osborne M. 2-hydroxyestrone: the “good” estrogen. J Endocrinol. 1996;150(suppl):S259–65.

    PubMed  CAS  Google Scholar 

  65. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A. 1985;82:6295–9.

    Article  PubMed  CAS  Google Scholar 

  66. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry 3rd J, Schunemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002;13:947–55.

    Article  PubMed  Google Scholar 

  67. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Pulkka A. Control of cell proliferation by steroids: The role of 17HSDs. Mol Cell Endocrinol. 2006;248:141–8.

    Article  PubMed  CAS  Google Scholar 

  68. Castagnetta LA, Granata OM, Lo Casto M, et al. Simple approach to measure metabolic pathways of steroids in living cells. J Chromatogr. 1991;572:25–39.

    Article  PubMed  CAS  Google Scholar 

  69. Castagnetta L, Granata OM, Polito L, Blasi L, Cannella S, Carruba G. Different conversion metabolic rates of testosterone are associated to hormone-sensitive status and -response of human prostate cancer cells. J Steroid Biochem. 1994;49:351–7.

    Article  CAS  Google Scholar 

  70. Carruba G, Adamski J, Calabrò M, Miceli MD, Cataliotti A, Bellavia V, Lo Bue A, Polito L, Castagnetta L. Molecular expression of 17βhydroxysteroid dehydrogenase types in relation to their activity in human prostate cancer cells. Mol Cell Endocrinol. 1997;135:51–7.

    Article  Google Scholar 

  71. Castagnetta L, Granata OM, Bellavia V, Amodio R, Scaccianoce E, Notarbartolo M, Follari MR, Miceli MD, Carruba G. Product of aromatase activity in intact LNCaP and MCF7 human cancer cells. J Steroid Biochem Mol Biol. 1997;61:287–92.

    Article  PubMed  CAS  Google Scholar 

  72. Ellem SJ, Risbridger GP. Aromatase and prostate cancer. Minerva Endocrinol. 2006;31:1–12.

    PubMed  CAS  Google Scholar 

  73. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res. 2002;62:1784–9.

    PubMed  CAS  Google Scholar 

  74. Ntais C, Polycarpou A, Ioannidis JP, et al. Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12:120–6.

    PubMed  CAS  Google Scholar 

  75. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004;59:69–76.

    Article  PubMed  CAS  Google Scholar 

  76. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms-Potential risk factors for breast and prostate cancer: A HuGE review. Am J Epidemiol. 2004;160:825–41.

    Article  PubMed  Google Scholar 

  77. Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al. Identifying susceptibility genes for prostate cancer: A family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005;14:2035–9.

    Article  PubMed  CAS  Google Scholar 

  78. Salam MT, Ursin G, Skinner EC, et al. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005;23:246–53.

    Article  PubMed  CAS  Google Scholar 

  79. Mononen N, Seppala EH, Duggal P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 2006;66:743–7.

    Article  PubMed  CAS  Google Scholar 

  80. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:969–78.

    Article  PubMed  CAS  Google Scholar 

  81. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165:171–7.

    Article  PubMed  CAS  Google Scholar 

  82. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer. 2003;106:375–8.

    Article  PubMed  CAS  Google Scholar 

  83. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, Plummer SJ, Casey G, Witte JS. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis. 2006;27:1842–8.

    Article  PubMed  CAS  Google Scholar 

  84. Gsur A, Feik E, Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol. 2004;21:414–23.

    Article  PubMed  CAS  Google Scholar 

  85. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26:1170–81.

    Article  PubMed  CAS  Google Scholar 

  86. Trosko JE. From adult stem cells to cancer stem cells. Ann N Y Acad Sci. 2006;1089:36–58.

    Article  PubMed  CAS  Google Scholar 

  87. Nanni S, Narducci M, Della PL, Moretti F, Grasselli A, De CP, Sacchi A, Pontecorvi A, Farsetti A. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest. 2002;110:219–27.

    PubMed  CAS  Google Scholar 

  88. Cavalieri EL, Rogan EG. Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol. 2010;6:75–91.

    Article  PubMed  CAS  Google Scholar 

  89. Noble RL. Prostate carcinoma of the Nb rat in relation to hormones. Int Rev Exp Pathol. 1982;23:113–59.

    PubMed  CAS  Google Scholar 

  90. Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate. 1982;3:563–8.

    Article  PubMed  CAS  Google Scholar 

  91. Bosland MC. Animal models for the study of prostate ­carcinogenesis. J Cell Biochem Suppl. 1992;16H:89–98.

    Article  PubMed  CAS  Google Scholar 

  92. Leav I, Merk FB, Kwan PW, Ho SM. Androgen supported ­estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate. 1989;15:23–40.

    Article  PubMed  CAS  Google Scholar 

  93. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague–Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylstilbestrol. Carcinogenesis. 1995;16:1311–7.

    Article  PubMed  CAS  Google Scholar 

  94. Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology. 2002;143:2093–105.

    Article  PubMed  CAS  Google Scholar 

  95. Ofner P, Bosland MC, Vena RL. Differential effects of diethylstilbestrol and estradiol-17β in combination with testosterone on rat prostate lobes. Toxicol Appl Pharmacol. 1992;112:300–9.

    Article  PubMed  CAS  Google Scholar 

  96. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 2000;60:6008–17.

    PubMed  CAS  Google Scholar 

  97. Prins GS. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer. 2008;15:649–59.

    Article  PubMed  CAS  Google Scholar 

  98. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989;49:3474–81.

    PubMed  CAS  Google Scholar 

  99. Iguchi T, Fukazawa Y, Tani N, Sato T, Ozawa S, Takasugi N, Shuin T, Kubotal Y, Petrov V. Effect of some hormonally active steroids upon the growth of LNCaP human prostate tumour cells in vitro. Cancer J. 1990;3:184–91.

    CAS  Google Scholar 

  100. Olea N, Sakabe K, Soto AM, Sonnenschein C. The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology. 1990;126:1457–63.

    Article  PubMed  CAS  Google Scholar 

  101. Carruba G, Pfeffer U, Fecarotta E, Coviello D, D’Amato E, Lo Casto M, Vidali G, Castagnetta L. Estradiol inhibits growth of hormone non responsive PC3 human prostate cancer cells. Cancer Res. 1994;54:1190–3.

    PubMed  CAS  Google Scholar 

  102. Castagnetta L, Miceli MD, Sorci C, Pfeffer U, Farruggio R, Oliveri G, Calabrò M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology. 1995;136:2309–19.

    Article  PubMed  CAS  Google Scholar 

  103. Ockrim J, Lalani E-N, Aubel P. Therapy insight: parenteral estrogen treatment for prostate cancer – a new dawn for an old therapy. Nat Clin Pract Oncol. 2006;3:552–63.

    Article  PubMed  CAS  Google Scholar 

  104. Lau KM, La Spina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60:3175–82.

    PubMed  CAS  Google Scholar 

  105. Escriva H, Bertrand S, Laudet V. The evolution of the nuclear receptor superfamily. Essays Biochem. 2004;40:11–26.

    PubMed  CAS  Google Scholar 

  106. Levin ER. Cell Localization, physiology and nongenomic actions of estrogen receptors. J Appl Physiol. 2001;91:1860–7.

    PubMed  CAS  Google Scholar 

  107. Herynk MH, Fuqua SAW. Estrogen receptor mutations in human disease. Endocr Rev. 2004;25:869–98.

    Article  PubMed  CAS  Google Scholar 

  108. Morani A, Warner M, Gustafsson JA. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med. 2008;264:128–42.

    Article  PubMed  CAS  Google Scholar 

  109. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537–51.

    Article  PubMed  CAS  Google Scholar 

  110. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A. 2001;98:6330–5.

    Article  PubMed  CAS  Google Scholar 

  111. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001;61:6777–82.

    PubMed  CAS  Google Scholar 

  112. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002;62:1370–6.

    PubMed  CAS  Google Scholar 

  113. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O’Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res. 2001;61:5331–5.

    PubMed  CAS  Google Scholar 

  114. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, ­dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001;159:79–92.

    Article  PubMed  CAS  Google Scholar 

  115. Zhu X, Leav I, Leung Y-K, Wu M, Liu Q, Gao Y, McNeal JE, Ho S-M. Dynamic regulation of estrogen receptor β expression by DNA methylation during prostate cancer development and ­metastasis. Am J Pathol. 2004;164:2003–12.

    Article  PubMed  CAS  Google Scholar 

  116. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta. 2004;1704:87–102.

    PubMed  CAS  Google Scholar 

  117. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, et al. Direct acetylation of estrogen receptor alpha hinge region by p300 ­regulates transactivation and hormone sensitivity. J Biol Chem. 2001;276:18375–83.

    Article  PubMed  CAS  Google Scholar 

  118. Leader JE, Wang C, Popov VM, Fu M, Pestell RG. Epigenetics and the estrogen receptor. Ann N Y Acad Sci. 2006;1089:73–87.

    Article  PubMed  CAS  Google Scholar 

  119. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997;94:3320–3.

    Article  PubMed  CAS  Google Scholar 

  120. Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol. 2001;195:138–46.

    Article  PubMed  CAS  Google Scholar 

  121. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98:1411–6.

    Article  PubMed  CAS  Google Scholar 

  122. Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA, Gronberg H. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res. 2006;12:1936–41.

    Article  PubMed  CAS  Google Scholar 

  123. Penot G, Le Péron C, Mérot Y, Grimaud-Fanouillère E, Ferrière F, Boujrad N, Kah O, Saligaut C, Ducouret B, Métivier R, Flouriot G. The human estrogen receptor-α isoform hERα46 antagonizes the proliferative influence of hERα66 in MCF7 breast cancer cells. Endocrinology. 2005;146:5474–84.

    Article  PubMed  CAS  Google Scholar 

  124. Wang ZY, Zhang XT, Shen P, Loggie BW, Chang YC, Deuel TF. A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalling. Proc Natl Acad Sci U S A. 2006;103:9063–8.

    Article  PubMed  CAS  Google Scholar 

  125. Peng B, Lu B, Leygue E, Murphy LC. Putative functional ­characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol. 2003;30:13–29.

    Article  PubMed  CAS  Google Scholar 

  126. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL, Ho SM. Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer. 2010;17:675–89.

    Article  PubMed  CAS  Google Scholar 

  127. Taylor SE, Patel II, Singh PB, Nicholson CM, Stringfellow HF, Gopala Krishna RK, Matanhelia SS, Martin-Hirsch PL, Martin FL. Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Public Health. 2010;7:3871–89.

    Article  PubMed  CAS  Google Scholar 

  128. Clarke BL, Khosla SK. New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol. 2009;21:374–9.

    Article  PubMed  CAS  Google Scholar 

  129. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst. 2007;99:350–6.

    Article  PubMed  CAS  Google Scholar 

  130. Gao W, Dalton JT. Ockam’s razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5α-­reductase? Mol Interv. 2007;7:10–3.

    Article  PubMed  CAS  Google Scholar 

  131. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103:843–52.

    Article  PubMed  CAS  Google Scholar 

  132. Ho SM. Estrogens and antiestrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004;91:491–503.

    Article  PubMed  CAS  Google Scholar 

  133. Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol. 2009;27:53–63.

    Article  PubMed  CAS  Google Scholar 

  134. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533–42.

    Article  PubMed  CAS  Google Scholar 

  135. Nilsson S, Gustafsson JÅ. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther. 2011;89:44–55.

    Article  PubMed  CAS  Google Scholar 

  136. Williams GP. The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. Eur J Cancer Prev. 2010;19:256–71.

    Article  PubMed  CAS  Google Scholar 

  137. Bradlow HL, Carruba G. Estrogens and human diseases. Ann N Y Acad Sci. 2006;1089:551.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Oncology Unit, Department of Oncology, ARNAS-Civico, Piazzale N. Leotta 2, Palermo, 90127, Italy

    Giuseppe Carruba M.D., Ph.D.

Authors
  1. Giuseppe Carruba M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Carruba M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Carruba, G. (2013). Estrogens in Prostate Cancer. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_30

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation